Ufenamate
(Synonyms: 氟芬那酸丁酯; Flufenamic acid butyl ester; Butyl flufenamate) 目录号 : GC37853
Ufenamate (Butyl flufenamate, Flufenamic acid butyl ester, Fenazol) is an anthranilic acid derivative with anti-inflammatory activity.
Cas No.:67330-25-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ufenamate (Butyl flufenamate, Flufenamic acid butyl ester, Fenazol) is an anthranilic acid derivative with anti-inflammatory activity.
| Cas No. | 67330-25-0 | SDF | |
| 别名 | 氟芬那酸丁酯; Flufenamic acid butyl ester; Butyl flufenamate | ||
| Canonical SMILES | O=C(OCCCC)C1=CC=CC=C1NC2=CC=CC(C(F)(F)F)=C2 | ||
| 分子式 | C18H18F3NO2 | 分子量 | 337.34 |
| 溶解度 | DMSO: ≥ 44 mg/mL (130.43 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9644 mL | 14.8218 mL | 29.6437 mL |
| 5 mM | 0.5929 mL | 2.9644 mL | 5.9287 mL |
| 10 mM | 0.2964 mL | 1.4822 mL | 2.9644 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Influence of Characteristics of Oily Vehicle on Skin Penetration of Ufenamate
Biol Pharm Bull 2017;40(2):220-226.PMID:28154263DOI:10.1248/bpb.b16-00817.
Skin penetration amounts of a highly lipophilic drug, Ufenamate, prepared in four oily vehicles, including white petrolatum (WP), liquid paraffin (LP), isopropyl myristate (IPM), and isocetyl stearate (ICS), were compared. Ufenamate was mixed in each vehicle at 5% and applied at a rate of 2 mg/cm2 to intact, stripped, and delipidized Yucatan micropig skin. The amounts of Ufenamate and IPM in the stratum corneum (SC), epidermis, and dermis were determined. The skin penetration amounts of Ufenamate from liquid oils were significantly higher than those from WP; the amounts of Ufenamate were in the order WP
Penetration of Ufenamate into Intact, Stripped, or Delipidized Skin Using Different Vehicles
Biol Pharm Bull 2015;38(10):1645-8.PMID:26424024DOI:10.1248/bpb.b15-00267.
The purpose of this study was to clarify the effect of skin condition on skin penetration of the very high lipophilic drug, Ufenamate (UF). UF was applied to stripped or delipidized skin using liquid paraffin (LP) or purified water containing polysorbate 80 at a dose of 2 µL/cm(2). We found that UF penetration into intact and stripped skin using a water vehicle was respectively 5 and 10 times higher than that using LP. UF is freely soluble in oil and insoluble in water; thus, activity in water is higher than that in LP. Therefore, it is useful to use a water-based vehicle for both intact sites and those with defective stratum corneum (SC). Conversely, we found that delipidization of SC decreased the penetration of UF significantly with both LP and water, and the amount measured in the epidermis was 1 µg/cm(2) with both vehicles. This indicates that UF is not suitable for so-called "dry skin." This study revealed clinically relevant differences in the penetration of UF into intact, stripped, or delipidized skin conditions.